38068712|t|Inhibitory Effects of Urolithins, Bioactive Gut Metabolites from Natural Polyphenols, against Glioblastoma Progression.
38068712|a|We previously reported that proinflammatory cytokines, particularly tumor necrosis factor (TNF)-alpha, promoted tumor migration, invasion, and proliferation, thus worsening the prognosis of glioblastoma (GBM). Urolithins, the potent metabolites produced by the gut from pomegranate polyphenols, have anticancer properties. To develop an effective therapy for GBM, this study aimed to study the effects of urolithins against GBM. Urolithin A and B significantly reduced GBM migration, reduced epithelial-mesenchymal transition, and inhibited tumor growth. Moreover, urolithin A and B inhibited TNF-alpha-induced vascular cell adhesion molecule (VCAM)-1 and programmed death ligand 1 (PD-L1) expression, thereby reducing human monocyte (HM) binding to GBM cells. Aryl hydrocarbon receptor (AhR) level had higher expression in patients with glioma than in healthy individuals. Urolithins are considered pharmacological antagonists of AhR. We demonstrated that the inhibition of AhR reduced TNF-alpha-stimulated VCAM-1 and PD-L1 expression. Furthermore, human macrophage condition medium enhanced expression of PD-L1 in human GBM cells. Administration of the AhR antagonist attenuated the enhancement of PD-L1, indicating the AhR modulation in GBM progression. The modulatory effects of urolithins in GBM involve inhibiting the Akt and epidermal growth factor receptor pathways. The present study suggests that urolithins can inhibit GBM progression and provide valuable information for anti-GBM strategy.
38068712	22	32	Urolithins	Chemical	-
38068712	73	84	Polyphenols	Chemical	MESH:D059808
38068712	94	106	Glioblastoma	Disease	MESH:D005909
38068712	188	221	tumor necrosis factor (TNF)-alpha	Gene	7124
38068712	232	237	tumor	Disease	MESH:D009369
38068712	310	322	glioblastoma	Disease	MESH:D005909
38068712	324	327	GBM	Disease	MESH:D005909
38068712	330	340	Urolithins	Chemical	-
38068712	402	413	polyphenols	Chemical	MESH:D059808
38068712	479	482	GBM	Disease	MESH:D005909
38068712	525	535	urolithins	Chemical	-
38068712	544	547	GBM	Disease	MESH:D005909
38068712	549	566	Urolithin A and B	Chemical	-
38068712	589	592	GBM	Disease	MESH:D005909
38068712	661	666	tumor	Disease	MESH:D009369
38068712	685	702	urolithin A and B	Chemical	-
38068712	713	722	TNF-alpha	Gene	7124
38068712	776	801	programmed death ligand 1	Gene	29126
38068712	803	808	PD-L1	Gene	29126
38068712	839	844	human	Species	9606
38068712	870	873	GBM	Disease	MESH:D005909
38068712	881	906	Aryl hydrocarbon receptor	Gene	196
38068712	908	911	AhR	Gene	196
38068712	944	952	patients	Species	9606
38068712	958	964	glioma	Disease	MESH:D005910
38068712	994	1004	Urolithins	Chemical	-
38068712	1051	1055	AhR.	Gene	196
38068712	1095	1098	AhR	Gene	196
38068712	1107	1116	TNF-alpha	Gene	7124
38068712	1128	1134	VCAM-1	Gene	7412
38068712	1139	1144	PD-L1	Gene	29126
38068712	1170	1175	human	Species	9606
38068712	1227	1232	PD-L1	Gene	29126
38068712	1236	1241	human	Species	9606
38068712	1242	1245	GBM	Disease	MESH:D005909
38068712	1275	1278	AhR	Gene	196
38068712	1320	1325	PD-L1	Gene	29126
38068712	1342	1345	AhR	Gene	196
38068712	1360	1363	GBM	Disease	MESH:D005909
38068712	1403	1413	urolithins	Chemical	-
38068712	1417	1420	GBM	Disease	MESH:D005909
38068712	1444	1447	Akt	Gene	207
38068712	1452	1484	epidermal growth factor receptor	Gene	1956
38068712	1527	1537	urolithins	Chemical	-
38068712	1550	1553	GBM	Disease	MESH:D005909
38068712	1608	1611	GBM	Disease	MESH:D005909
38068712	Association	MESH:D005909	207
38068712	Positive_Correlation	7124	7412
38068712	Association	MESH:D005909	7124
38068712	Positive_Correlation	196	7412
38068712	Positive_Correlation	MESH:D005910	196
38068712	Positive_Correlation	29126	7124
38068712	Association	196	29126
38068712	Association	196	7124
38068712	Association	MESH:D005909	196
38068712	Association	MESH:D005909	1956
38068712	Association	MESH:D005909	29126
38068712	Positive_Correlation	MESH:D009369	7124

